Skip to content

KYMR changes

Pick any two versions below to diff them.

View the full Nov 15, 2026 version
Price
$115.31
Discount category
Close to intrinsic value
Intrinsic value source
AI estimate
Next earnings
Jan 29, 2027
Next earnings is estimate
Yes
Company name
added: Kymera Therapeutics
Sector
added: Biotechnology: oral protein degrader medicines
About
added: Kymera Therapeutics, Inc. (KYMR) is based in Watertown, Massachusetts. It is a clinical-stage biotechnology company. It develops oral small molecule medicines that cause the body to break down the proteins that drive a disease (targeted protein degradation), first in immunological diseases. Its main program is KT-621, a once-daily oral degrader of STAT6, the protein that drives Type 2 inflammation. KT-621 is in Phase 2b trials in atopic dermatitis (AD) and asthma. KT-579 degrades IRF5 and is for lupus and other autoimmune diseases. Sanofi develops KT-485, an IRAK4 degrader, and Gilead develops KT-200, a CDK2 degrader for cancer, under license agreements. Kymera has no product sales. Its revenue comes from these collaborations, and its net loss was $311.4 million in 2025. The common stock trades on Nasdaq in US dollars. Kymera files 10-K and 10-Q reports.
Thesis
added: The market values Kymera mainly on KT-621, its oral STAT6 degrader, because a pill that works as well as injected biologics in atopic dermatitis and asthma can have very large sales. But Kymera has no approved product, and its patient data so far came from a Phase 1b trial with 28 days of dosing. The AI estimate weighs a case where KT-621 fails against cases where it succeeds. For the value to rise, three things must be true. BROADEN2, the Phase 2b trial in about 200 patients with atopic dermatitis, must show a strong drop in the EASI score at week 16 with a clean safety profile. Kymera must start Phase 3 trials in AD by mid-2027, and the BREADTH trial must show a benefit in asthma in late 2027. KT-579 must show effects on disease biology in lupus patients. BROADEN2 topline data come by year-end 2026, and this is the main test. Weak data can remove most of the value above cash, and strong data can raise it.
Valuation
added: The intrinsic value for Kymera Therapeutics is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Kymera with the SEC. Kymera has no product sales, so the method is a sum of parts: cash, plus a risk-adjusted value of KT-621, plus a value for the rest of the pipeline, divided by the share count. The value of KT-621 is its assumed peak yearly sales, times the probability that it reaches the market, times 3. The multiple of 3 is an assumption that allows for the years until peak sales, the costs of trials and sales, taxes and discounting. The Q3 2026 10-Q gives cash, cash equivalents and marketable securities of $1,646 million at September 30, 2026, and no debt. It gives 85,371,397 shares outstanding at October 23, 2026, and 15,815,253 pre-funded warrants at September 30, 2026. The warrants have a nominal exercise price, so the estimate uses 101.2 million shares. It leaves out stock options. The Q3 2026 release of October 29, 2026 (Form 8-K) gives a net loss of $132.0 million for Q3 2026, a cash runway into 2029 and BROADEN2 topline data by year-end 2026. It says that more than 140 million patients live with Type 2 diseases such as AD and asthma. The peak sales, the probabilities, the pipeline values, the multiple and the weights are assumptions. The estimate does not subtract future losses from cash, because the multiple allows for them. The low case assumes that BROADEN2 fails and KT-621 has no value, with $1,000 million for KT-579, the partnered programs and research. It gives $26.15 per share. The base case assumes peak sales of $6,000 million for KT-621 in AD, asthma and other Type 2 diseases, a probability of 50% and $1,500 million for the rest of the pipeline. It gives $120.04 per share. The high case assumes peak sales of $10,000 million, a probability of 65% and $2,500 million for the rest. It gives $233.69 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $124.98 per share. Kymera has patents and know-how in oral protein degraders, and Sanofi and Gilead license its programs. But it has no approved product and no sales, and other companies develop oral drugs for the same diseases. The estimate does not count on a durable advantage. As of Nov 14, 2026.
Risks
added: Most of the value depends on KT-621. If BROADEN2 or later trials show weak efficacy or a safety problem, the value can fall toward cash. Injected biologics already treat atopic dermatitis and asthma, and other companies develop oral drugs for the same diseases. KT-621 must work about as well as these drugs and be safe for long-term use to win patients. Kymera loses money: net loss was $262.4 million in the first nine months of 2026. Phase 3 trials cost more, and Kymera can sell new shares, for example under its $500 million at-the-market program. Targeted protein degradation is a new type of medicine. Regulators can ask for more data on long-term safety, which can delay approval. Milestones from Sanofi and Gilead depend on their decisions and on trial results, so they may not occur.
Balance sheet
added: Cash: $1.6B Debt: $0.0M Net cash: $1.6B At September 30, 2026, Kymera had cash, cash equivalents and marketable securities of $1,646 million and no debt. Total liabilities were $152.7 million, mostly accrued expenses and lease liabilities, and stockholders' equity was $1,614.5 million. Net cash used in operating activities was $220.8 million in the nine months to September 30, 2026. By September 30, 2026, Kymera sold 2,032,140 shares for gross proceeds of about $219 million under its current at-the-market program. It expects its cash to fund operations into 2029. As of Sep 30, 2026.
Checkpoints
added: Dec 2026 (estimate): KT-621 BROADEN2 topline data. Pending. Watch: KT-621 gives a clear, dose-related drop in the EASI score at week 16 against placebo, with a clean safety profile, and this passes; a small benefit or a safety signal fails. Jan 29, 2027 (estimate): Q4 2026 results. Pending. Watch: Kymera confirms the start of Phase 3 trials in AD by mid-2027 and keeps its cash runway into 2029, and this passes; a delay of Phase 3 or a shorter runway fails. Q4 2027 (estimate): KT-621 BREADTH asthma data. Pending. Watch: KT-621 improves lung function or other asthma measures against placebo in BREADTH, and this passes; no benefit in asthma fails.
Recent events
added: Oct 29, 2026: Kymera reported Q3 2026 results and positive Phase 1 data for KT-579 in healthy volunteers. KT-579 gave median IRF5 degradation of 90% or more in blood at multiple doses, and its safety was comparable to placebo. Net loss was $132.0 million, and cash, cash equivalents and investments were $1.6 billion at September 30, 2026. The last patient completed the week 16 visit of BROADEN2, with topline data by year-end 2026. Aug 5, 2026: Kymera reported Q2 2026 results. Collaboration revenue was $65.0 million, which included a $45 million option fee from Gilead for KT-200 and a $20 million milestone from Sanofi after the first dose of KT-485 in a Phase 1 trial. Net loss was $61.2 million. Jul 27, 2026: Kymera named Terence Rooney, MD, a former immunology leader at Johnson & Johnson, as Chief Medical Officer. Jared Gollob, MD, retires and stays as an advisor until the end of 2026. Jun 25, 2026: Kymera completed enrollment in BROADEN2 nearly six months ahead of plan and moved its topline data to year-end 2026 from mid-2027. It plans to start Phase 3 trials in AD by mid-2027. Apr 30, 2026: Kymera reported Q1 2026 results. Gilead exercised its option to license KT-200, and the FDA gave KT-621 Fast Track designation in moderate to severe asthma. Cash was $1.55 billion at March 31, 2026. Feb 26, 2026: Kymera reported 2025 results, with a net loss of $311.4 million and $1.6 billion of cash at December 31, 2025. It also signed an at-the-market sales agreement with TD Cowen for up to $500 million of common stock. Jan 13, 2026: Kymera set its 2026 goals, including KT-579 Phase 1 data in the second half of 2026, and said that its cash runway goes into 2029.